Our study also found that MAPK signaling pathway was closely related to osimertinib resistance of NSCLC, and RPS6KA1, CACNA1B and MAPK8IP3 were significantly enriched in “MAPK signaling pathway” (Table 3). Here, RPS6KA1 is linked to non-small cell lung carcinoma.